The Food and Drug Administration yesterday approved a new pre-exposure prophylaxis (PrEP) for certain adults and adolescents who do not have HIV but are at risk for infection from sex. The drug, Descovy, previously was approved for use with other antiretoviral drugs to treat HIV infection in adults and pediatric patients. “PrEP drugs are highly effective when taken as indicated in the drug labeling and can prevent HIV infection,” said Jeffrey Murray, M.D., deputy director for the division of antiviral products at FDA’s Center for Drug Evaluation and Research. “This approval provides more prevention options for certain patients at-risk for acquiring HIV.”

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday updated the number of people with confirmed or probable lung injuries associated with electronic…
Headline
The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living…
Headline
The Centers for Disease Control and Prevention today released updated interim clinical guidance for U.S. health care providers evaluating and caring for…
Headline
The Centers for Disease Control and Prevention this week reported a record 2.5 million cases of chlamydia, gonorrhea and syphilis in the U.S. in 2018,…
Headline
Only one in three U.S. pregnant women receive both the flu and whooping cough vaccines as recommended, according to a Vital Signs report released today by the…
Headline
The U.S. has retained its measles elimination status for another year, the Department of Health and Human Services announced Friday.